Sharing Patient Voices at Pfizer Canada’s National Meeting
Our Voice at the Table
On December 2, ALK Positive Canada had the honour of joining Pfizer’s National Meeting to share the lived realities of ALK‑positive lung cancer in Canada. From diagnosis to daily life on targeted therapies, we spoke about the challenges patients face and the practical support needed for timely, equitable care.
What We Shared
During the meeting, we highlighted:
- Navigating Testing and Diagnosis: The steps patients take to get an accurate diagnosis.
- Managing Side Effects: Real-life TKI experiences—from varied side effects to when dose adjustments are needed. More research on dose optimization could help patients manage treatment more effectively.
- Coordinated Care: The need for clear communication with oncology teams.
- Equitable Access: Barriers across provinces that affect patient care.
Building Awareness and Connection
We also introduced ALK Positive Canada to more members of Pfizer’s team, sharing what we accomplished this year and our vision for the future. This included:
- Building trusted educational resources.
- Hosting expert-led webinars.
- Amplifying patient stories to highlight lived experience.
Looking Ahead
We are grateful to Pfizer for creating a space that truly centres patient voices. In 2025, these first steps in education, community support, and advocacy have laid the foundation for continued collaboration—ensuring patient experiences shape better care and support for all.